GSK agreed to acquire global rights to a trispecific T-cell engager from Chimagen Biosciences, committing up to $750 million to secure a Phase 1-ready program aimed at multiple myeloma. The asset is designed to engage three targets rather than two, with GSK arguing the architecture could provide benefits versus existing bispecific approaches. The company’s strategy is to move quickly into clinical execution, positioning the candidate for Phase 1 development next year. The licensing follows GSK’s earlier engagement with Chimagen’s T-cell engager platform. The deal underscores big pharma’s continuing appetite for targeted immuno-oncology constructs that can differentiate on potency, safety profile, and depth of response in difficult-to-treat hematologic cancers.